Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Tarsus Pharmaceuticals, Inc. First Quarter 2026 Financial Results Conference Call.
Tarsus Pharmaceuticals Inc. (TARS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,666,768 | $230,786,378 | +2% | 3.36% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 2,775,649 | $174,699,348 | +9% | 3.27% |
| 3. | Tang Capital Management Kevin C. Tang | 1,568,266 | $98,706,662 | +32% | 4.48% |
| 4. | Millennium Management Israel Englander | 1,427,124 | $89,823,185 | +153% | 0.03% |
| 5. | Vestal Point Capital Ryan Wilder | 1,050,000 | $66,087,000 | +425% | 1.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.96 | 1,000 | $18,960.00 | 3,000 | 2023-12-15 | Filing | |
| $16.80 | 9,506 | $159,700.80 | 15,866 | 2023-08-15 | Filing | |
| $16.29 | 6,360 | $103,604.40 | 6,360 | 2022-09-14 | Filing | |
| $16.03 | 12,040 | $193,001.20 | 12,040 | 2022-09-14 | Filing | |
| $13.50 | 100,000 | $1,350,000.00 | 100,000 | 2022-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $61.81 | 5,418 | $334,886.58 | 847,991 | 2026-06-17 | Filing | |
| $61.24 | 4,582 | $280,601.68 | 853,409 | 2026-06-17 | Filing | |
| $60.95 | 14,396 | $877,436.20 | 56,801 | 2026-06-16 | Filing | |
| $62.08 | 2,954 | $183,384.32 | 2,233 | 2026-06-15 | Filing | |
| $62.94 | 1,928 | $121,348.32 | 106,786 | 2026-06-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,856,137 | $242,705,264 | 0% | |
| 2. | 3,357,059 | $211,293,293 | 1.8% | |
| 3. | 2,808,796 | $176,833,783 | 0.07% | |
| 4. | 1,827,082 | $114,996,594 | 0.01% | |
| 5. | 1,793,064 | $112,855,448 | 0% |
News See All
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating
On February 25, 2026, Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Tarsus Pharmaceuticals, Inc.
10 Fastest Growing NASDAQ Stocks to Buy
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Tarsus Fourth Quarter and Full Year 2025 Financial Results Conference Call. As a reminder, this call is being recorded. [Operator Instructions].
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Tarsus' Third Quarter 2025 Financial Results Conference Call. As a reminder this call is being recorded.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus Second Quarter 2025 Earnings Conference Call. As a reminder, this call is being recorded.
11 Best Breakout Stocks to Buy According to Analysts
Stock markets have been on edge in response to the US President's aggressive trade war that has resulted in trade tariffs aimed at settling the trade deficit.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript
Operator: Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call.
Hedge Fund Resource Center